Each year, there are an estimated 180,000 recurrent strokes in the United States. The study identified several modifiable factors that are associated with stroke survivors' compliance in taking medication that can help prevent recurrent stroke. Researchers hope those factors will prove effective targets for improving compliance.
The paper appears online this week in the Archives of Neurology, one of the JAMA/Archives journals, and is scheduled to appear in the journal's December print issue.
"There is very little known about how stroke patients feel about their medications and all of the complicated reasons that people may or may not stay on those medications," said Cheryl D. Bushnell, M.D., M.H.S., an associate professor of neurology at Wake Forest Baptist and lead author on the study. "Physicians can prescribe all of the right medications, but if patients don't take them, they're not receiving the benefits of prevention."
So, Bushnell and colleagues, including researchers at Duke Clinical Research Institute, designed a study similar to those done to investigate medication compliance in patients with coronary artery disease. They looked at compliance issues from the patients' perspective, as well as system and provider issues, such as what type of doctor the patients saw, what kind of follow-up care they had and the patients' understanding of their medications and why they were taking them.
The researchers studied 2,598 patients from the Adherence Evaluation After Ischemic Stroke–Longitudinal (AVAIL) Registry to evaluate how many stroke patients continued taking their prescribed medications to prevent a second stroke three months after their discharge from the hospital. The chance of a second stroke, the authors noted, is greatest during the first three months after the initial attack.
The authors found that about 75 percent of those studied had continued with their full regimen of medications – usually including an aspirin or other type of blood thinner, blood pressure medication and cholesterol lowering medication – three months after discharge. But they also found that nearly 20 percent of patients had stopped taking one or more of their prescribed medications, while 3.5 percent of patients weren't taking any of their medications at three months.
"This is actually much better than what we would expect based on our clinical experience," Bushnell said. "It's surprising at how high the compliance rate was. As physicians, we often see a lot more patients stopping their medicine on their own or having it stopped by a physician, so we think this may have been a best-case scenario, but it's still concerning. That's a lot of people at high risk of having a second stroke who are not doing everything they can to prevent it." Bushnell explained that the participating hospitals were all involved in quality improvement activities for stroke care, so they were highly motivated to have good stroke outcomes. It is possible that the patients at these hospitals were seen for their follow-up appointments by the same doctor who prescribed the medications at discharge, unlike many hospitals where follow-up care is handled by the patient's normal doctor.
Researchers learned from the study that multiple factors were associated with persistence in continuing secondary medication regimens, including the presence of cardiovascular disease and risk factors prior to stroke, having insurance, having a better quality of life, being prescribed fewer discharge medications and having an understanding of why these medications were prescribed and how to refill them. Additionally, increasing age, lesser stroke disability and fewer financial hardships were also associated with persistence in continuing medication regimens.
Bushnell also explained that many times, patients aren't discontinuing their medications on their own, but rather their doctors may be discontinuing them.
"I think that a lot of patients will tell their doctors that the medication doesn't agree with them or they can't take it for some other reason and the doctor takes them off of it," Bushnell said. "Many doctors try to limit the number of medications a patient has to take, especially when a lot of the same medicines can be used to treat both stroke and coronary disease."
In fact, patients who had a diagnosis of coronary disease or some other chronic disease before their stroke and were accustomed to taking daily medications to treat that condition were more likely to continue taking their new medications after stroke, the study showed.
"Patients who are taken off-guard by a stroke, and are given a lot of new medications and a new diagnosis, can get a little overwhelmed and the result can be discontinuation of one or more medications," she said. "But we learned that patients who actually understand why they are being prescribed each new medication and how to go about refilling their prescriptions are more compliant. This is a really important teaching moment. We, as doctors, need to make sure we are giving patients more specific information upon discharge. We need to explain things in more detail, such as, 'This blood pressure medication we're asking you to take isn't just for lowering your blood pressure, it's for preventing another stroke.'
"This study has really changed the way I interact with my patients," Bushnell added. "I've started asking the sometimes uncomfortable questions about whether they can afford their medications and if they're taking them. If they aren't, I'm asking why. My passion is to try to prevent recurrent stroke and to understand the patients' and caregivers' perspectives and the barriers and areas we can intervene in to make sure that people have the knowledge and resources to keep taking their medicines. Hopefully, we as providers can improve patients' medication compliance through better communication and by being aware of the factors associated with medication discontinuation."
The researchers' next study will reveal the compliance results one year after hospital discharge.
This study was conceived and designed by the AVAIL team, researchers at Duke Clinical Research Institute, the project executive committee and an American Heart Association representative. The AVAIL analyses were also supported in part by a grant from the Agency for Healthcare Research and Quality.
Media Contacts: Jessica Guenzel, firstname.lastname@example.org, (336) 716-3487; Bonnie Davis, email@example.com, (336) 716-4977; or Main Number (336) 716-4587.
Wake Forest University Baptist Medical Center (www.wfubmc.edu) is an academic health system comprised of Wake Forest University Health Sciences, which operates the university's School of Medicine, Wake Forest University Physicians and North Carolina Baptist Hospital. U.S. News & World Report ranks the School of Medicine among the nation's best medical and osteopathic schools: 33rd in primary care, 44th in research, 23rd for its physician assistant program, and 11th for its joint program with the UNC-Greensboro to train nurse anesthetists. Best Doctors in America includes 214 of the Wake Forest medical school faculty. The institution is in the top third in funding by the National Institutes of Health and fourth in the Southeast in revenues from its licensed intellectual property. The Medical Center has been ranked as one of "America's Best Hospitals" by U.S. News & World Report since 1993.
Jessica Guenzel | EurekAlert!
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Earth Sciences
07.12.2016 | Earth Sciences
07.12.2016 | Materials Sciences